Table 1.
Baseline features of eligible studies in systematic review.
| Study | Registration | Phase | Enrollment | Treatment | Systemic regimens | Network nodes | Sample size | PS (0/1) | Siewert classification (%) | OS-HR |
|---|---|---|---|---|---|---|---|---|---|---|
| Cats et al.17 | NCT00407186 | III | 2007–2015 | Surgery plus perioperative chemoradiotherapy | Capecitabine plus cisplatin/oxaliplatin plus epirubicin | PeriCRT | 67 | 0–1 | II versus III (NA) | 1.12 (95% CI 0.61–2.06) |
| Surgery plus perioperative chemotherapy | Capecitabine plus cisplatin/oxaliplatin plus epirubicin | PeriCT | 68 | |||||||
| Fuchs et al.18 | NCT00052910 | III | 2002–2009 | Surgery plus adjuvant chemoradiotherapy | 5-FU plus cisplatin plus epirubicin | Not included | 55 | 0–2 | NA (NA) | 1.02 (95% CI 0.62–1.68) |
| Surgery plus adjuvant chemoradiotherapy | 5-FU plus leucovorin | 65 | ||||||||
| Stahl et al.2 | NA | III | 2000–2005 | Surgery plus preoperative chemoradiotherapy | 5-FU plus cisplatin | PreCRT | 60 | 33/24 | I versus II (55% versus 45%) | 0.65 (95% CI 0.42–1.01) |
| Surgery plus preoperative chemotherapy | 5-FU plus cisplatin | PreCT | 59 | 38/17 | I versus II (54% versus 46%) | |||||
| Cunningham et al.19 | NCT00450203 | III | 2007–2014 | Surgery plus perioperative chemotherapy | Capecitabine plus cisplatin plus epirubicin plus bevacizumab | PeriCTT | 271 | 0–1 | I versus II versus III (24% versus 35% versus 41%) | 0.98 (95% CI 0.77–1.25) |
| Surgery plus perioperative chemotherapy | Capecitabine plus cisplatin plus epirubicin | PeriCT | 265 | I versus II versus III (23% versus 39% versus 38%) | ||||||
| Noh et al.20 | NCT00411229 | III | 2006–2009 | Surgery plus adjuvant chemotherapy | Capecitabine plus oxaliplatin | PostCT | 24 | 0–2 | NA (NA) | 0.63 (95% CI 0.09–4.45) |
| Surgery | None | S | ||||||||
| Ychou et al.3 | NCT00002883 | III | 1995–2003 | Surgery plus perioperative chemotherapy | 5-FU plus cisplatin | PeriCT | 70 | 0–1 | NA (NA) | 0.57 (95% CI 0.39–0.83) |
| Surgery | None | S | 74 | |||||||
| Cunningham et al.21 | ISRCTN93793971 | III | 1994–2002 | Surgery plus perioperative chemotherapy | 5-FU plus cisplatin plus epirubicin | PeriCT | 28 | 0–1 | NA (NA) | 0.48 (95% CI 0.27–0.86) |
| Surgery | None | S | 30 | |||||||
| MRCOCWG22 | NA | III | 1992–1998 | Surgery plus preoperative chemotherapy | 5-FU plus cisplatin | PreCT | 40 | 0–1 | NA (NA) | 0.63 (95% CI 0.38–1.06) |
| Surgery | None | S | 42 |
MRCOCWG: Medical Research Council Oesophageal Cancer Working Group; NA: not available; OS-HR: overall survival (hazard ratio).
Nodes: PeriCRT: perioperative chemoradiotherapy; PeriCT: perioperative chemotherapy; PreCRT: preoperative chemoradiotherapy; PreCT: preoperative chemotherapy; PeriCTT: perioperative chemotherapy plus targeted medication; PostCT: postoperative chemotherapy; S: surgery alone.
Since Fuchs and colleagues 2017 could not form a network with other studies, it was eliminated from the network calculation and was only narratively discussed.